Latest Alzheimer's News
- Sudoku, Crosswords Make Your Brain Years Younger
- Exercise, Healthy Eating Can Reduce Dementia Risk
- 'Robopets' Bring Companionship to Nursing Homes
- Hormone Therapy for Prostate Cancer, Dementia Risk
- Alzheimer's Spread Like an Infection Through Brain
- Want More News? Sign Up for MedicineNet Newsletters!
TUESDAY, March 7, 2017 (HealthDay News) -- A drug used to treat Alzheimer's disease should not be prescribed to people with milder mental impairment without first giving them a genetic test, a new study urges.
Donepezil could speed mental decline in someone with mild cognitive impairment who has a specific genetic variation, according to Sophie Sokolow, an associate professor at the UCLA School of Nursing.
She and her colleagues found that patients with the K-variant of the butyrylcholinesterase (BChE) gene who took donepezil deteriorated faster than those who took a placebo.
Donepezil is approved in the United States to treat Alzheimer's disease but not mild cognitive impairment -- the stage between normal age-related decline and dementia. However, doctors often prescribe it "off-label" for patients with mild cognitive impairment, the study authors said.
For this study, the researchers examined data from a U.S. government-funded study published in 2005 that assessed donepezil as a possible treatment for mild cognitive impairment.
The findings reinforce the importance of physicians discussing the possible benefits and risks of donepezil with their patients, the researchers said in a university news release.
The study was published recently in the Journal of Alzheimer's Disease. Funding was provide by the U.S. National Institute on Aging.
-- Robert Preidt
Copyright © 2017 HealthDay. All rights reserved.